Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Intensity Therapeutics, Inc. ( (INTS) ) has shared an update.
On August 4, 2025, Intensity Therapeutics, Inc. announced it raised approximately $6.6 million in July 2025 through an At-the-Market offering. The funds extend the company’s cash runway into the second half of 2026 and support ongoing clinical trials. The average sales price per share was over 10% higher than the June 2025 public offering, reflecting favorable market conditions.
The most recent analyst rating on (INTS) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies. The company utilizes proprietary non-covalent conjugation technology to create therapies designed to kill tumors and enhance immune system recognition of cancers. Intensity’s lead product, INT230-6, is being tested in various clinical trials, aiming to transform cancer treatment paradigms.
Average Trading Volume: 3,211,662
Technical Sentiment Signal: Sell
For an in-depth examination of INTS stock, go to TipRanks’ Overview page.